Suzuken (9987) Q1 2027 earnings summary

Executive summary

• Net sales rose 6.1% year-over-year to ¥628,962 million, driven by growth in the prescription drug market and strong specialty drug sales.

• Operating profit declined 25.0% year-over-year to ¥4,190 million due to higher procurement and operating costs, as well as increased digital and R&D investments.

• Profit attributable to owners of parent fell 10.6% year-over-year to ¥3,381 million.

• Ordinary profit decreased 12.3% year-over-year to ¥5,074 million.

• Comprehensive income increased 29.3% year-over-year to ¥3,218 million.

• A new Medium-Term Management Plan was launched, focusing on evolving into a next-generation distributor, rebuilding the business portfolio, and strengthening the management foundation.

Financial highlights

• Gross profit was ¥43,349 million, nearly flat year-over-year, with a gross margin of 6.89%.

• SG&A expenses increased 3.9% year-over-year to ¥39,158 million.

• Basic earnings per share for the quarter was ¥49.99, down from ¥52.63 a year earlier.

• Total assets increased to ¥1,195,684 million as of June 30, 2026, up ¥39,917 million from March 31, 2026.

• Net assets slightly decreased to ¥415,888 million, with an equity-to-asset ratio of 34.8%.

Outlook and guidance

• Revenue estimates for nearly 90% of customers are provisional, based on requested pricing, as final sales prices have not been settled.

• Full-year net sales forecast is ¥2,563,000 million (up 3.1% year-over-year), with operating profit projected at ¥31,200 million (up 14.2%).

• Profit attributable to owners of parent is forecast at ¥25,000 million (up 34.4%), with basic EPS of ¥184.81 (reflecting a stock split).

• No changes to previously announced forecasts as of this report.

• Management notes ongoing risks from inflation, procurement costs, and uncertainties in price settlements.